Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 225 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How Joining a Clinical Trial Helped Me Find Hope While Living... December 5, 2023 A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 A celebration of peer review September 21, 2021 Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical... June 3, 2026 Load more HOT NEWS New on NCI Websites for July 2019 Bjorn Saven: “By supporting early career researchers to do their jobs... Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in...
